Home
About
Back
About
Meet the Team
Back
Senior Leadership
Board of Directors
Scientific Advisory Board
Personalized Cancer Vaccine Clinical Advisor
History of Providence
Foundations of Providence
Technology
Back
mRNA Medicines Ecosystem
mRNA Medicines Platform
Next-Gen LNP
Validated Manufacturing
Pipeline
Business Development
Back
Partnerships
Funders
Investors
News & Media
Back
Press Releases
Publications
Media
Careers & Culture
Contact
Careers & Culture
Contact
Home
About
About
Meet the Team
Senior Leadership
Board of Directors
Scientific Advisory Board
Personalized Cancer Vaccine Clinical Advisor
History of Providence
Foundations of Providence
Technology
mRNA Medicines Ecosystem
mRNA Medicines Platform
Next-Gen LNP
Validated Manufacturing
Pipeline
Business Development
Partnerships
Funders
Investors
News & Media
Press Releases
Publications
Media
Careers & Culture
Contact
Publications
and Scientific Papers
All
2024
2023
2022
2021
Comparison of modified T7 RNAPs to develop a simplified, cost effective, robust mRNA production process
Written on
October 28, 2024
Read more
Novel LNP delivered mRNA vaccine elicits potent immune responses and cures established tumor in mice
Written on
October 28, 2024
Read more
Next-Generation LNP's Induce Effective Anti-Tumor T cell Responses
Written on
October 02, 2024
Read more
Next-Generation mRNA-LNP Vaccine Prototype Achieves Tumor Clearance in a GBM Mouse Model
Written on
October 02, 2024
Read more
Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study
Written on
March 07, 2024
Read more